Thymulin

What it is

Thymulin (also known as facteur thymique sérique or FTS) is a nine-amino-acid peptide originally isolated from thymic epithelium. Thymulin requires zinc binding for biological activity (sometimes designated FTS-Zn). The peptide was identified in the 1970s during a period of intense research interest in thymic peptides and immune function.

Thymulin is not FDA-approved for any use in the United States. Most research has been in immunology laboratories and animal models; human research is very limited.

Mechanism of action

Proposed mechanisms come from laboratory and animal research, in which thymulin has been reported to influence T-cell function and differentiation. Its mechanisms are less well characterized than those of thymosin alpha-1. In laboratory studies, the peptide appears inactive without zinc binding.

Clinical evidence

The human research base on thymulin is limited. Early clinical research interest in autoimmune diseases and immune deficiency states did not lead to established medical uses, and well-controlled human trials establishing effectiveness and safety are lacking.

Why we don’t prescribe it at The Tide

Thymulin is not FDA-approved, and the available evidence is insufficient to establish its effectiveness or safety in people. This entry is provided for educational purposes only.

Side effects and contraindications

Human safety has not been established in well-controlled trials, and long-term effects are unknown. Because thymulin is reported to affect immune function, theoretical concerns have been raised for people with autoimmune conditions, malignancy, or organ transplants on immunosuppression, and during pregnancy. Products sold outside regulated channels may vary in purity, dose, and sterility.